ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Novartis has acquired IFM Due, a subsidiary of IFM Therapeutics, for $90 million up front and milestone payments that could be worth $745 million. The deal grants Novartis rights to IFM Due’s full collection of stimulators of interferon genes (STING) antagonists in development. The small molecules target the innate immune system and address rare, inflammation-driven diseases like Aicardi-Goutières syndrome. The class of drug candidates could also target more common diseases like chronic obstructive pulmonary disease, IFM Due says.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter